PointState Capital’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

PointState Capital’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-238,700	Closed	-$15.9M	–	207
2018 Q1	$15.9M	Buy	+238,700	New	+$13.8M	0.17%	81
2017 Q3	–	Sell	-43,000	Closed	-$2.57M	–	181
2017 Q2	$2.57M	Sell	43,000 -152,469	-78%	-$8.52M	0.03%	113
2017 Q1	$10.4M	Buy	+195,469	New	+$11.6M	0.11%	95
2016 Q4	–	Sell	-125,000	Closed	-$7.51M	–	185
2016 Q3	$7.51M	Buy	+125,000	New	+$7.21M	0.08%	95

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PointState Capital's ONCE Position: Q2 2018 in Review

PointState Capital sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2018, closing a stake of 238,700 shares — an estimated $15.9M sold.

PointState Capital first reported a position in ONCE in Q3 2016 and held it in 4 quarters. The position peaked at $15.9M in Q1 2018. 172 funds tracked by Wall St. Rank hold ONCE as of Q2 2018.

PointState Capital reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
PointState Capital sold 238,700 Spark Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $15.9M.
PointState Capital first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2016 and held it in 4 quarters.
PointState Capital's Spark Therapeutics, Inc. Common Stock position peaked at $15.9M in Q1 2018.
172 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2018.

Based on PointState Capital's 13F filing for Q2 2018, filed 14 Aug 2018.